Evogene (EVGN) Competitors $1.27 +0.03 (+2.42%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$1.26 -0.01 (-0.79%) As of 09/12/2025 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVGN vs. CARM, SNES, TOMZ, ENFY, GURE, NITO, BSLK, CNEY, TANH, and GAMCWShould you be buying Evogene stock or one of its competitors? The main competitors of Evogene include Carisma Therapeutics (CARM), Senestech (SNES), TOMI Environmental Solutions (TOMZ), Enlightify (ENFY), Gulf Resources (GURE), N2OFF (NITO), Bolt Projects (BSLK), CN Energy Group. (CNEY), Tantech (TANH), and Golden Arrow Merger (GAMCW). Evogene vs. Its Competitors Carisma Therapeutics Senestech TOMI Environmental Solutions Enlightify Gulf Resources N2OFF Bolt Projects CN Energy Group. Tantech Golden Arrow Merger Carisma Therapeutics (NASDAQ:CARM) and Evogene (NASDAQ:EVGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation. Do analysts prefer CARM or EVGN? Carisma Therapeutics presently has a consensus price target of $1.93, indicating a potential upside of 414.57%. Evogene has a consensus price target of $3.50, indicating a potential upside of 175.59%. Given Carisma Therapeutics' higher probable upside, equities research analysts plainly believe Carisma Therapeutics is more favorable than Evogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.71Evogene 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is CARM or EVGN more profitable? Evogene has a net margin of -211.61% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-254.28% N/A -192.17% Evogene -211.61%-109.96%-38.47% Does the media favor CARM or EVGN? In the previous week, Evogene had 1 more articles in the media than Carisma Therapeutics. MarketBeat recorded 3 mentions for Evogene and 2 mentions for Carisma Therapeutics. Evogene's average media sentiment score of 0.97 beat Carisma Therapeutics' score of 0.45 indicating that Evogene is being referred to more favorably in the news media. Company Overall Sentiment Carisma Therapeutics Neutral Evogene Positive Which has more risk & volatility, CARM or EVGN? Carisma Therapeutics has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500. Comparatively, Evogene has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Which has preferable earnings & valuation, CARM or EVGN? Evogene has lower revenue, but higher earnings than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$10.77M1.45-$60.48M-$1.56-0.24Evogene$8.51M0.80-$16.49M-$2.25-0.56 Do institutionals & insiders have more ownership in CARM or EVGN? 44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 7.4% of Evogene shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryCarisma Therapeutics beats Evogene on 9 of the 16 factors compared between the two stocks. Get Evogene News Delivered to You Automatically Sign up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVGN vs. The Competition Export to ExcelMetricEvogeneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.65M$3.19B$5.84B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-0.5621.4375.4125.98Price / Sales0.80429.44515.81181.13Price / CashN/A46.6837.5660.44Price / Book0.469.6112.156.29Net Income-$16.49M-$53.29M$3.29B$271.07M7 Day Performance5.57%0.13%0.73%3.87%1 Month Performance-6.62%5.55%4.99%5.49%1 Year Performance-55.90%10.44%62.53%25.86% Evogene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVGNEvogene3.0435 of 5 stars$1.27+2.4%$3.50+175.6%-55.9%$6.65M$8.51M-0.56140Short Interest ↓CARMCarisma Therapeutics2.6185 of 5 stars$0.36-10.6%$1.93+442.3%-63.3%$14.50M$19.63M-0.2220Short Interest ↑Gap UpSNESSenestech2.8484 of 5 stars$5.06+0.7%$10.00+97.8%+66.7%$24.95M$1.86M-0.9330Short Interest ↓TOMZTOMI Environmental Solutions3.0283 of 5 stars$0.83-5.7%$3.50+321.2%+12.7%$16.69M$7.74M-3.6120Positive NewsENFYEnlightify0.343 of 5 stars$0.98-4.7%N/AN/A$15.48M$95.85M-0.79424Gap DownGUREGulf Resources1.1292 of 5 stars$0.77+2.7%N/A-34.0%$10.28M$7.66M-0.31420Short Interest ↓Gap UpNITON2OFF1.5875 of 5 stars$0.22+0.5%N/A-37.8%$7.67M$210K0.002News CoveragePositive NewsBSLKBolt Projects0.5554 of 5 stars$3.61-3.4%N/A-84.4%$7.55M$1.37M-1.4112Positive NewsGap DownCNEYCN Energy Group.1.135 of 5 stars$2.00-10.8%N/A-79.2%$6.27M$50.96M0.00160Short Interest ↓High Trading VolumeTANHTantech1.1295 of 5 stars$2.05+0.3%N/A-68.7%$178K$42.94M0.0070Negative NewsShort Interest ↓Gap DownGAMCWGolden Arrow MergerN/A$0.05+12.3%N/AN/A$0.00N/A0.0012Gap Up Related Companies and Tools Related Companies CARM Competitors SNES Competitors TOMZ Competitors ENFY Competitors GURE Competitors NITO Competitors BSLK Competitors CNEY Competitors TANH Competitors GAMCW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVGN) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evogene Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EVGN Stock Alerts